Key features and details
- Expression system: Escherichia coli
- Purity: > 95% SDS-PAGE
- Active: Yes
- Tags: GST tag N-Terminus
- Suitable for: SDS-PAGE, WB, ELISA
Product nameRecombinant Hepatitis B Virus E Antigen protein
ab91273 is immunoreactive with sera of HBV-infected individuals. It contains the Hepatitis B Virus HBe adw immunodominant region.
Purity> 95 % SDS-PAGE.
Expression systemEscherichia coli
Protein lengthFull length protein
Predicted molecular weight44 kDa including tags
Amino acids8 to 165
TagsGST tag N-Terminus
Additional sequence informationThe protein contains immunodominant region of HBV e antigen.
Our Abpromise guarantee covers the use of ab91273 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Constituents: 0.79% Tris HCl, 50% Glycerol, 0.35% Sodium chloride, 0.307% Glutathione, 0.25% Sarkosyl
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- Core antigen
- Core protein
- HBe antigen
RelevanceHepatitis B e-antigen (HBeAg) is a viral protein associated with HBV infections. Unlike the surface antigen, the e-antigen is found in the blood only when there are viruses also present. When the virus goes into “hiding,” the e-antigen will no longer be present in the blood. HBeAg is often used as a marker of ability to spread the virus to other people (infectivity). Measurement of e-antigen may also be used to monitor the effectiveness of HBV treatment; successful treatment will usually eliminate HBeAg from the blood and lead to development of antibodies against e-antigen (anti-HBe). There are some types (strains) of HBV that do not make e-antigen; these are especially common in the Middle East and Asia. In areas where these strains of HBV are common, testing for HBeAg is not very useful.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab91273 has been referenced in 6 publications.
- Li Z et al. MicroRNA-1271-5p alleviates the malignant development of hepatitis B virus-mediated liver cancer via binding to AQP5. Mol Med Rep 23:N/A (2021). PubMed: 33760167
- Xie X et al. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis. BMC Med 19:247 (2021). PubMed: 34649530
- Chen W et al. Negative feedback loop of ERK/CREB/miR-212-3p inhibits HBeAg-induced macrophage activation. J Cell Mol Med 24:10935-10945 (2020). PubMed: 32767729
- Wijaya RS et al. KLRG1+ natural killer cells exert a novel antifibrotic function in chronic hepatitis B. J Hepatol N/A:N/A (2019). PubMed: 30905683
- Li F et al. HBV infection suppresses the expression of inflammatory macrophage miR-210. Mol Med Rep 19:1833-1839 (2019). PubMed: 30592291
- Ren ZQ et al. Establishment of Magnetic Microparticles-Assisted Time-Resolved Fluoroimmunoassay for Determinating Biomarker Models in Human Serum. PLoS One 10:e0130481 (2015). Human . PubMed: 26103625